{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:27:23Z","timestamp":1790512043422,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,12,7]]},"DOI":"10.1038\/s41416-021-01585-6","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T15:29:27Z","timestamp":1634743767000},"page":"1657-1665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma"],"prefix":"10.1038","volume":"125","author":[{"given":"St\u00e9phanie","family":"Durand-Panteix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Monteil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Sage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Garot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Saidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Torgue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-4427","authenticated-orcid":false,"given":"Michel","family":"Cogne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5877-8937","authenticated-orcid":false,"given":"Isabelle","family":"Quelven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"1585_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380:848\u201357.","journal-title":"Lancet"},{"key":"1585_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1053\/j.seminhematol.2010.01.001","volume":"47","author":"SA Beers","year":"2010","unstructured":"Beers SA, Chan CHT, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47:107\u201314.","journal-title":"Semin Hematol"},{"key":"1585_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.beha.2006.05.002","volume":"19","author":"TE Witzig","year":"2006","unstructured":"Witzig TE. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Pract Res Clin Haematol. 2006;19:655\u201368.","journal-title":"Best Pract Res Clin Haematol."},{"key":"1585_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/08830185.2019.1588266","volume":"38","author":"M Eskian","year":"2019","unstructured":"Eskian M, Khorasanizadeh M, Zinzani PL, Illidge TM, Rezaei N. Novel methods to improve the efficiency of radioimmunotherapy for non-Hodgkin lymphoma. Int Rev Immunol. 2019;38:79\u201391.","journal-title":"Int Rev Immunol"},{"key":"1585_CR5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1158\/1078-0432.CCR-12-0298","volume":"19","author":"KE Baidoo","year":"2013","unstructured":"Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted \u03b1-particle radiation therapy. Clin Cancer Res. 2013;19:530\u20137.","journal-title":"Clin Cancer Res."},{"key":"1585_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1053\/j.semnuclmed.2019.09.002","volume":"50","author":"JG Jurcic","year":"2020","unstructured":"Jurcic JG. Targeted alpha-particle therapy for hematologic malignancies. Semin Nucl Med. 2020;50:152\u201361.","journal-title":"Semin Nucl Med"},{"key":"1585_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s13277-011-0286-y","volume":"33","author":"Y-S Kim","year":"2012","unstructured":"Kim Y-S, Brechbiel MW. An overview of targeted alpha therapy. Tumour Biol. 2012;33:573\u201390.","journal-title":"Tumour Biol"},{"key":"1585_CR8","doi-asserted-by":"crossref","unstructured":"Nelson BJB, Andersson JD, Wuest F. Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications. Pharmaceutics. 2020;13:49.","DOI":"10.3390\/pharmaceutics13010049"},{"key":"1585_CR9","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1039\/c0dt01387k","volume":"40","author":"K Yong","year":"2011","unstructured":"Yong K, Brechbiel MW. Towards translation of 212Pb as a clinical therapeutic; getting the lead in! Dalton Trans. 2011;40:6068\u201376.","journal-title":"Dalton Trans."},{"key":"1585_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0969-8051(99)00086-4","volume":"27","author":"LL Chappell","year":"2000","unstructured":"Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, Brechbiel MWSynthesis. characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol. 2000;27:93\u2013100.","journal-title":"Nucl Med Biol."},{"key":"1585_CR11","doi-asserted-by":"crossref","unstructured":"Quelven I, Monteil J, Sage M, Saidi A, Mounier J, Bayout A, et al. 212Pb Alpha-radioimmunotherapy targeting CD38 in multiple myeloma: a preclinical study. J Nucl Med. 2019;61:1058\u201365.","DOI":"10.2967\/jnumed.119.239491"},{"key":"1585_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1089\/cbr.2013.1531","volume":"29","author":"RF Meredith","year":"2014","unstructured":"Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, et al. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm. 2014;29:12\u20137.","journal-title":"Cancer Biother Radiopharm"},{"key":"1585_CR13","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/COC.0000000000000353","volume":"41","author":"RF Meredith","year":"2018","unstructured":"Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, et al. Safety and outcome measures of first-in-human intraperitoneal \u03b1 radioimmunotherapy with 212Pb-TCMC-trastuzumab. Am J Clin Oncol. 2018;41:716\u201321.","journal-title":"Am J Clin Oncol"},{"key":"1585_CR14","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2008-08-175125","volume":"113","author":"D Dayd\u00e9","year":"2009","unstructured":"Dayd\u00e9 D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood. 2009;113:3765\u201372.","journal-title":"Blood."},{"key":"1585_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nmeth.1455","volume":"7","author":"DJ Langford","year":"2010","unstructured":"Langford DJ, Bailey AL, Chanda ML, Clarke SE, Drummond TE, Echols S, et al. Coding of facial expressions of pain in the laboratory mouse. Nat Methods. 2010;7:447\u20139.","journal-title":"Nat Methods"},{"key":"1585_CR16","doi-asserted-by":"publisher","first-page":"9995","DOI":"10.1002\/anie.201004243","volume":"49","author":"S Jeger","year":"2010","unstructured":"Jeger S, Zimmermann K, Blanc A, Gr\u00fcnberg J, Honer M, Hunziker P, et al. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem Int Ed Engl. 2010;49:9995\u20137.","journal-title":"Angew Chem Int Ed Engl"},{"key":"1585_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1021\/bc400574z","volume":"25","author":"P Dennler","year":"2014","unstructured":"Dennler P, Chiotellis A, Fischer E, Br\u00e9geon D, Belmant C, Gauthier L, et al. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug Chem. 2014;25:569\u201378.","journal-title":"Bioconjug Chem."},{"key":"1585_CR18","doi-asserted-by":"publisher","first-page":"e0139835","DOI":"10.1371\/journal.pone.0139835","volume":"10","author":"H Carpenet","year":"2015","unstructured":"Carpenet H, Cuvillier A, Monteil J, Quelven I. Anti-CD20 immunoglobulin G radiolabeling with a 99mTc-tricarbonyl core: in vitro and In vivo evaluations. PLoS ONE. 2015;10:e0139835.","journal-title":"PLoS ONE"},{"key":"1585_CR19","unstructured":"FDA. Clinical review of BLA reference NO. BLA 97\u20130260 AND BLA 97\u20130244. 1997 - U.S. Food and Drug Administration Search Results."},{"key":"1585_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2967\/jnumed.108.056606","volume":"50","author":"F van der Have","year":"2009","unstructured":"van der Have F, Vastenhouw B, Ramakers RM, Branderhorst W, Krah JO, Ji C, et al. U-SPECT-II: an ultra-high-resolution device for molecular small-animal imaging. J Nucl Med. 2009;50:599\u2013605.","journal-title":"J Nucl Med"},{"key":"1585_CR21","first-page":"1927","volume":"92","author":"B Coiffier","year":"1998","unstructured":"Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927\u201332.","journal-title":"Blood."},{"key":"1585_CR22","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1182\/blood-2007-01-066803","volume":"110","author":"J Dahle","year":"2007","unstructured":"Dahle J, Borreb\u00e6k J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland \u00d8S, et al. Targeted cancer therapy with a novel low-dose rate \u03b1-emitting radioimmunoconjugate. Blood. 2007;110:2049\u201356.","journal-title":"Blood."},{"key":"1585_CR23","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1182\/blood-2010-05-282327","volume":"116","author":"SI Park","year":"2010","unstructured":"Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood. 2010;116:4231\u20139.","journal-title":"Blood."},{"key":"1585_CR24","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1054\/bjoc.2000.1453","volume":"83","author":"E Aurlien","year":"2000","unstructured":"Aurlien E, Larsen RH, Kvalheim G, Bruland OS. Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate (211)At-rituximab against non-Hodgkin\u2019s lymphoma cells. Br J Cancer. 2000;83:1375\u20139.","journal-title":"Br J Cancer."},{"key":"1585_CR25","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2014-11-612770","volume":"125","author":"DJ Green","year":"2015","unstructured":"Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, et al. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood. 2015;125:2111\u20139.","journal-title":"Blood."},{"key":"1585_CR26","doi-asserted-by":"publisher","first-page":"e0230526","DOI":"10.1371\/journal.pone.0230526","volume":"15","author":"AF Maaland","year":"2020","unstructured":"Maaland AF, Saidi A, Torgue J, Heyerdahl H, Stallons TAR, Kolstad A, et al. Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin\u2019s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003. PLoS ONE. 2020;15:e0230526.","journal-title":"PLoS ONE"},{"key":"1585_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1089\/cbr.2009.0746","volume":"25","author":"P Kletting","year":"2010","unstructured":"Kletting P, Meyer C, Reske SN, Glatting G. Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling. Cancer Biother Radiopharm. 2010;25:279\u201387.","journal-title":"Cancer Biother Radiopharm."},{"key":"1585_CR28","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jmir.2019.07.006","volume":"50","author":"N Pandit-Taskar","year":"2019","unstructured":"Pandit-Taskar N. Targeted radioimmunotherapy and theranostics with alpha emitters. J Med Imaging Radiat Sci. 2019;50:S41\u20134.","journal-title":"J Med Imaging Radiat Sci"},{"key":"1585_CR29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00259-018-4220-z","volume":"46","author":"JC Dos Santos","year":"2019","unstructured":"Dos Santos JC, Sch\u00e4fer M, Bauder-W\u00fcst U, Lehnert W, Leotta K, Morgenstern A, et al. Development and dosimetry of 203Pb\/212Pb-labelled PSMA ligands: bringing \u00ab the lead \u00bb into PSMA-targeted alpha therapy? Eur J Nucl Med Mol Imaging. 2019;46:1081\u201391.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"1585_CR30","doi-asserted-by":"crossref","unstructured":"Banerjee SR, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M, et al. Preclinical evaluation of 203\/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2020;61:80\u20138.","DOI":"10.2967\/jnumed.119.229393"},{"key":"1585_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N. Engl J Med. 2017;376:125\u201335.","journal-title":"N. Engl J Med"},{"key":"1585_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1089\/cbr.2019.3405","volume":"35","author":"W Wojdowska","year":"2020","unstructured":"Wojdowska W, Karczmarczyk U, Balog L, Sawicka A, P\u00f6st\u00e9nyi Z, Kov\u00e1cs-Ha\u00e1sz V, et al. Impact of DOTA-chelators on the antitumor activity of 177Lu-DOTA-rituximab preparations in lymphoma tumor-bearing mice. Cancer Biother Radiopharm. 2020;35:558\u201362.","journal-title":"Cancer Biother Radiopharm."},{"key":"1585_CR33","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1158\/1535-7163.MCT-17-0554","volume":"16","author":"A Krasniqi","year":"2017","unstructured":"Krasniqi A, D\u2019Huyvetter M, Xavier C, Jeught KV, der, Muyldermans S, Heyden JVD, et al. Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma. Mol Cancer Ther. 2017;16:2828\u201339.","journal-title":"Mol Cancer Ther."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01585-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01585-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01585-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T14:08:27Z","timestamp":1638886107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01585-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12,7]]}},"alternative-id":["1585"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01585-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"assertion":[{"value":"28 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Amal Saidi and Julien Torgue are Orano Med employees. No other potential conflicts of interest relevant to this article exist.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All applicable international, national and institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}